Salud financiera de hoja de balance de DermTech
Salud financiera controles de criterios 4/6
DermTech tiene un patrimonio de los accionistas total de $57.2M y una deuda total de $0.0, lo que sitúa su ratio deuda-patrimonio en 0%. Sus activos y pasivos totales son $121.9M y $64.8M respectivamente.
Información clave
0%
Ratio deuda-patrimonio
US$0
Deuda
| Ratio de cobertura de intereses | n/a |
| Efectivo | US$55.86m |
| Patrimonio | US$57.18m |
| Total pasivo | US$64.76m |
| Activos totales | US$121.93m |
Actualizaciones recientes sobre salud financiera
We're A Little Worried About DermTech's (NASDAQ:DMTK) Cash Burn Rate
Mar 02
Companies Like DermTech (NASDAQ:DMTK) Could Be Quite Risky
Sep 18Can DermTech (NASDAQ:DMTK) Afford To Invest In Growth?
Jun 14We're Keeping An Eye On DermTech's (NASDAQ:DMTK) Cash Burn Rate
Jan 16Will DermTech (NASDAQ:DMTK) Spend Its Cash Wisely?
Oct 11Recent updates
We're A Little Worried About DermTech's (NASDAQ:DMTK) Cash Burn Rate
Mar 02Investors Don't See Light At End Of DermTech, Inc.'s (NASDAQ:DMTK) Tunnel And Push Stock Down 28%
Mar 02Revenues Working Against DermTech, Inc.'s (NASDAQ:DMTK) Share Price
Dec 28Companies Like DermTech (NASDAQ:DMTK) Could Be Quite Risky
Sep 18Can DermTech (NASDAQ:DMTK) Afford To Invest In Growth?
Jun 14Need To Know: The Consensus Just Cut Its DermTech, Inc. (NASDAQ:DMTK) Estimates For 2023
May 10DermTech, Inc. (NASDAQ:DMTK) Not Doing Enough For Some Investors As Its Shares Slump 37%
May 06We're Keeping An Eye On DermTech's (NASDAQ:DMTK) Cash Burn Rate
Jan 16Analyst Forecasts Just Became More Bearish On DermTech, Inc. (NASDAQ:DMTK)
Nov 08Will DermTech (NASDAQ:DMTK) Spend Its Cash Wisely?
Oct 11DermTech grants stock options
Oct 11Diving Into DermTech
Sep 01Earnings Release: Here's Why Analysts Cut Their DermTech, Inc. (NASDAQ:DMTK) Price Target To US$23.80
Aug 10DermTech: Approaching An All Or Nothing Moment
Jun 13We're Keeping An Eye On DermTech's (NASDAQ:DMTK) Cash Burn Rate
Jun 04DermTech - Taking A Second Look At The Growth Thesis
Mar 31DermTech: Adoption Headwinds And Earnings Misses
Dec 23Companies Like DermTech (NASDAQ:DMTK) Are In A Position To Invest In Growth
Dec 02DermTech - Game Changer, Set To Become The Leader In Skin Diagnostics
Sep 15We Think DermTech (NASDAQ:DMTK) Can Afford To Drive Business Growth
Sep 03DermTech: Transforming The Melanoma Diagnosis Landscape
Aug 31DermTech: Becoming More Appealing, Despite Nosebleed Valuation
Aug 09DermTech appoints former Myriad Genetics executive as new chief medical officer
Jun 16We're Not Very Worried About DermTech's (NASDAQ:DMTK) Cash Burn Rate
Jun 05DermTech initiated buy at BTIG on the potential of PLA test
May 03DermTech rises 18% on report Cigna covering early melanoma detection test
Apr 27Análisis de la situación financiera
Pasivos a corto plazo: Los activos a corto plazo ($61.8M) de DMTK superan a sus pasivos a corto plazo ($13.4M).
Pasivo a largo plazo: Los activos a corto plazo de DMTK ($61.8M) superan a sus pasivos a largo plazo ($51.3M).
Historial y análisis de deuda-patrimonio
Nivel de deuda: DMTK está libre de deudas.
Reducción de la deuda: DMTK actualmente no tiene deuda, sin embargo, no podemos comparar con hace 5 años ya que no disponemos de datos de ese periodo.
Hoja de balance
Análisis de cash runway
En el caso de las empresas que de media han sido deficitarias en el pasado, evaluamos si tienen al menos 1 año de cash runway.
Cash runway estable: DMTK tiene menos de un año de cash runway basado en su flujo de caja libre actual.
Pronóstico de cash runway: DMTK tiene menos de un año de cash runway si el flujo de caja libre sigue reduciéndose a tasas históricas de 39.4% cada año